Novel advances in prostate cancer are changing treatment decisions across disease settings.
As patients we have the opportunity to join leading experts from Duke, Mayo Clinic, and Dana-Farber for a free, live in-person + virtual CME symposium on May 29, 2026 in Chicago.
Topics include therapeutic expansion, emerging strategies, and practical clinical insights.
Register now: PeerView.com/2026Prostate-Share
In new research presented at the 41st Annual Congress of the European Association of Urology in March 2026, ARTIFICIAL intelligence (AI) integrated with magnetic resonance imaging (MRI) significantly improved biopsy decision-making in prostate cancer diagnosis.
The retrospective study analysed patients who underwent pre-biopsy MRI between 2021 and 2024. Researchers focused on two key measures: biopsy selectivity, which reflects how well imaging identifies clinically significant cancer (Grade Group ≥2), and biopsy efficiency, which compares significant cancer detection with less serious or benign findings.
Across both diagnostic thresholds tested, AI support improved overall performance. Notably, the greatest improvement occurred among less experienced readers. With AI decision support, basic readers achieved efficiency scores comparable to expert radiologists, suggesting that AI may help standardise prostate cancer diagnosis across different levels of clinical expertise.
The results suggested that AI-assisted bpMRI interpretation could help clinicians better identify patients who would benefit from biopsy while reducing unnecessary procedures. Read the article at: https://www.emjreviews.com/urology/news/eau-2026-ai-support-enhances-prostate-cancer-biopsy-selection/
The latest Guidelines for Patients:Prostate Cancer Screening from the U.S. National Comprehensive Cancer Network (NCCN) are now available for free download at: https://www.nccn.org/patients/guidelines/content/PDF/prostate-screening-patient.pdf
Please review for your information and distribution through your networks.
